ARVINAS, INC.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company dedicated to developing novel protein degradation therapeutics through its proprietary PROTAC (PROteolysis TArgeting Chimera) platform technology. The company's website is www.arvinas.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ARVINAS, INC. does
In the company’s own words
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company dedicated to developing novel protein degradation therapeutics through its proprietary PROTAC (PROteolysis TArgeting Chimera) platform technology. The company's website is www.arvinas.com.
Arvinas focuses on discovering and developing targeted protein degradation therapeutics designed to harness the body's natural protein disposal system to selectively degrade disease-causing proteins. The company's PROTAC Discovery Engine represents an integrated suite of tools and capabilities including target selection, E3 ligase knowledge bases, advanced screening capabilities, proprietary linker technology (ANGLE), library-enabled PROTAC design (LEAP), computational modeling (PROTACify), proteomics capabilities, and in vivo optimization tools (PIVOT).
The company's clinical pipeline includes five primary programs. ARV-102 is an oral PROTAC LRRK2 degrader targeting neurodegenerative diseases including Parkinson's disease and progressive supranuclear palsy. ARV-806 is a novel PROTAC targeting mutant KRAS G12D in solid tumors including pancreatic, colorectal, and non-small cell lung cancer. ARV-393 is an oral PROTAC BCL6 degrader for relapsed/refractory non-Hodgkin lymphoma. ARV-027 targets the polyglutamine-expanded androgen receptor in skeletal muscle. Vepdegestrant, the company's most advanced candidate, targets the estrogen receptor for ER+/HER2- breast cancer and has received FDA acceptance of its New Drug Application with a PDUFA action date of June 5, 2026.
Arvinas also maintains several preclinical programs including ARV-6723 targeting HPK1 and a pan-KRAS degrader targeting multiple KRAS variants. The company has strategic collaborations with Pfizer, Genentech, and F. Hoffmann-La Roche Ltd. for research, development, and potential commercialization of certain product candidates. The company also maintains a license agreement with Novartis Pharma AG related to luxdegalutamide (ARV-766).
As a clinical-stage company, Arvinas has not yet generated revenue from product sales. The company reported net losses of $80.8 million, $198.9 million, and $367.3 million for the years ended December 31, 2025, 2024, and 2023, respectively.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEW HAVEN, CT
- Fiscal year end
- December
- CIK
- 1655759
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ARVINAS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ARVINAS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ARVINAS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ARVINAS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ARVINAS, INC.'s last four quarterly filings that the numbers alone won't show?”